Genmab's Rina-S Shows Promising 50% Response in Advanced Endometrial Cancer Trial

Genmabs updated results from the RAINFOL-01 trial show that rinatabart sesutecan (Rina-S), an antibody-drug conjugate, achieved a 50% response rate in advanced endometrial cancer patients, marking a significant advancement in treatment options.

• At the European Society for Medical Oncology Congress, Genmab presented data indicating a 50% response rate in heavily pretreated patients with advanced endometrial cancer from cohort B2 of the RAINFOL-01 trial.
• Rinatabart sesutecan (Rina-S) is an investigational antibody-drug conjugate specifically targeting folate receptor alpha (FRa), delivering a TOPO1 inhibitor payload to treat advanced endometrial cancer.
• The promising results from this cohort study underscore the potential of Rina-S as a viable treatment option for patients with limited alternatives in advanced endometrial cancer.